Taysha Gene Therapies (NASDAQ:TSHA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Taysha Gene Therapies (NASDAQ:TSHA) from a sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other equities research analysts have also recently issued reports on TSHA. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. UBS Group set a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Wells Fargo & Company lifted their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Chardan Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.09.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $4.53 on Friday. The firm has a market cap of $1.30 billion, a P/E ratio of -13.33 and a beta of 1.02. The business’s 50 day moving average is $4.63 and its 200-day moving average is $4.58. The company has a current ratio of 12.23, a quick ratio of 12.23 and a debt-to-equity ratio of 0.20. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. The business had revenue of $5.49 million during the quarter, compared to the consensus estimate of $1.89 million. Taysha Gene Therapies had a negative return on equity of 56.64% and a negative net margin of 1,144.97%. Equities research analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Transactions at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 26,918 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $124,091.98. Following the transaction, the insider owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sean P. Nolan sold 41,312 shares of the business’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $190,448.32. Following the completion of the transaction, the chief executive officer directly owned 2,908,257 shares of the company’s stock, valued at approximately $13,407,064.77. This trade represents a 1.40% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 598,623 shares of company stock valued at $2,822,188. 3.78% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vestal Point Capital LP boosted its position in shares of Taysha Gene Therapies by 150.0% during the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock worth $75,625,000 after acquiring an additional 8,250,000 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Taysha Gene Therapies by 2.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock valued at $75,310,000 after purchasing an additional 309,031 shares in the last quarter. Vanguard Group Inc. raised its position in Taysha Gene Therapies by 3.3% during the fourth quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock valued at $72,973,000 after purchasing an additional 418,192 shares in the last quarter. Octagon Capital Advisors LP lifted its stake in Taysha Gene Therapies by 17.7% during the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after purchasing an additional 1,892,500 shares during the last quarter. Finally, State Street Corp lifted its stake in Taysha Gene Therapies by 49.1% during the fourth quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after purchasing an additional 3,553,619 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.